Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vertex Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2022 was 10.92.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vertex Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.
The historical rank and industry rank for Vertex Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
VRTX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66 Med: 2.91 Max: 26.61
Current: 10.92
During the past 13 years, Vertex Pharmaceuticals's highest Cash to Debt Ratio was 26.61. The lowest was 0.66. And the median was 2.91.
VRTX's Cash-to-Debt is ranked worse than 50.51% of 1558
companies
in the Biotechnology industry
Industry Median: 11.43
vs VRTX: 10.92
Vertex Pharmaceuticals Cash-to-Debt Historical Data
The historical data trend for Vertex Pharmaceuticals's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Cash-to-Debt
3.44
5.40
5.76
7.15
8.06
Vertex Pharmaceuticals Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Cash-to-Debt
7.51
7.94
8.06
9.44
10.92
Competitive Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Cash-to-Debt Distribution
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vertex Pharmaceuticals Cash-to-Debt Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.36(0.81%) Volume: 990,779 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VRTX has been successfully added to your 
